Two leading biopharmaceutical companies in Hefei National High-Tech Industry Development Zone, Meiya Optoelectronics and Xingmou Biology, have achieved remarkable milestones in their respective fields.

Meiya Optoelectronics' mobile head CT, approved by the National Medical Products Administration as a Class III medical device, addresses the limitations of traditional CT equipment with its portability and adaptability to various clinical settings. This breakthrough enhances imaging capabilities for cranial, oral, and ENT scans, revolutionizing bedside diagnostics.

Meanwhile, Xingmou Biology's gene therapy drug, named XMVA09 Injection, received Class I innovative drug approval from the National Medical Products Administration. This groundbreaking treatment targets age-related macular degeneration, offering a dual-specificity approach and intravitreal injection for improved efficacy.

These advancements underscore the innovation and research prowess of biopharmaceutical enterprises in Hefei high-tech zone, providing new avenues of hope for patients. The zone's biopharmaceutical and high-end medical device industries are flourishing, with approximately 700 companies forming a comprehensive industrial chain.

Looking ahead, Hefei high-tech zone remains committed to fostering the growth of these sectors, poised to make significant contributions to global healthcare.

The recent achievements mark a significant stride forward for Hefei High-tech zone's biopharmaceutical landscape, promising enhanced healthcare solutions and a brighter future for patients worldwide.